论文部分内容阅读
目的:探讨低分子量肝素治疗急性脑梗死的疗效和安全性。方法:对170例急性脑梗死患者以低分子量肝素(速碧林)0.4-0.6ml皮下注射,2次/日,疗程(10±2)d。结果:治疗前后ESS和ADL积分均有显著差异;梗死灶面积较大者的ESS积分增加率显著高于梗死灶面积较小者;治疗时间越早,疗效相对也提高。治愈31例(18.23％),基本治愈22例(12.94％),显效39例(22.94％),总有效率75.88％。2例全身轻度出血(1.2％),1例症状性脑出血(0.6％),部分病人有一过性谷丙转氨酶增高。结论:低分子肝素治疗急性脑梗死安全、有效。
Objective: To investigate the efficacy and safety of low molecular weight heparin in the treatment of acute cerebral infarction. Methods: A total of 170 patients with acute cerebral infarction were injected subcutaneously with low molecular weight heparin 0.4-0.6ml twice daily for 10 ± 2 days. Results: The ESS and ADL scores were significantly different before and after treatment. The increase rate of ESS score in the area with larger infarct size was significantly higher than that in the area with smaller infarct size. The earlier the treatment was, the more the effect was. There were 31 cases (18.23%) cured, 22 cases (12.94%) basically cured, 39 cases (22.94%) markedly effective and the total effective rate was 75.88%. 2 cases of mild systemic bleeding (1.2%), 1 case of symptomatic intracerebral hemorrhage (0.6%), some patients had transient alanine aminotransferase increased. Conclusion: LMWH is safe and effective in the treatment of acute cerebral infarction.